In 2019, the number of A-share pharmaceutical companies listed in Hong Kong stock market reached a record high

Original | Daniel In 2019, great changes have taken place in China's capital market, the launch of science and technology innovation board, the acceleration of IPO review, and the increasing attraction of Hong Kong Stock Exchange.. This paper summarizes the listing of Chinese pharmaceutical enterprises in a shares, Hong Kong shares and US shares in 2019, and looks forward to 2020 In 2019, there are 21 pharmaceutical and biological companies listed on A-share market in China, among which 17 are listed on science and technology innovation board (including those that will be held in 2019), and only 4 are listed on other A-share sectors It is worth noting that since the launch of science and technology innovation board in July 2019, all pharmaceutical enterprises have chosen to log on to science and technology innovation board Figure 1 A-share IPO of China's pharmaceutical and biological companies in 2019 (unit: 100 million yuan) Data source: Ifind, Zhongkang Industrial Capital Research Center From the perspective of financial data, compared with the previous companies listed in other sectors of a share, the distribution of net profits of 17 companies listed in science and technology innovation board in 2019 is significantly more scattered, including the 2018 loss of Zejing pharmaceutical, which shows that the key to audit the companies to be listed under the registration system is no longer finance and scale At the beginning of the year, the overall profitability of four pharmaceutical companies listed in other sectors of A-share is stronger, and their net profits in 2018 are all over 100 million yuan In fact, in 2019, 17 biomedical enterprises listed on the science and technology innovation board also have bright financial data The "H + a" share company haohaishengke ranked first in the list of all newly listed companies on the science and technology innovation board with a net profit of 455 million yuan In 2018, Huaxi biology had a net profit of 424 million yuan, ranking second, with a year-on-year growth of 90.7% Among them, the net profits of South micro medicine and Haier biology were the same The specific growth rate reached 81.36% and 89.93% respectively In addition to the 20.34% year-on-year decrease in net profit of Bairen pharmaceutical in 2018, the net profit of other enterprises has increased The net profit of Pumen technology is 81 million yuan, an increase of 70.52% year-on-year In terms of the industry, among the 21 pharmaceutical enterprises listed in A-share market in 2019, there are as many as 11 medical devices, accounting for 52.4% On the one hand, it reflects the development trend of China's medical device industry, and also reflects the recognition of the capital market, especially the scientific and technological innovation board for innovative medical enterprises In addition to A-share, there are 19 other biomedical companies listed in Hong Kong in 2019, and 4 biomedical companies listed in the United States Figure 2 IPO of Chinese bio companies in US and Hong Kong stocks in 2019 (unit: RMB 100 million) Data source: Ifind, Zhongkang Industrial Capital Research Center The newly listed biomedical enterprises in Hong Kong stock market are mainly pharmaceutical (8 companies) and medical care equipment and services (7 companies) Compared with A-share, the proportion of newly listed loss making enterprises in Hong Kong stock market is significantly increased, among which the innovative drug enterprises in the research and development stage are the main contributors Hanlin pharmaceutical, a leading pharmaceutical manufacturer in China, made a net profit of 1.9 billion yuan in 2018, with an annual growth rate of 19.28% It became the most profitable biomedical company listed in Hong Kong in 2019 In the same year, the net profit of KANGLONG chemical, a leading cro company in China, was 336 million yuan, with an annual growth rate of 53.59% In 2019, four biomedical companies were listed in the United States, mainly medical equipment and services and biopharmaceuticals The profitability of these four enterprises is not good In 2018, the net profit of Yimei international lost RMB 252 million In 2018, the net profit of xingfulai, a pharmaceutical, biotechnology and life science company, decreased by 4.33%, and the net profit of neooxygen technology increased six times, with a total net profit of RMB 55 million In the past 10 years, pharmaceutical companies have mainly listed in China's A-share and Hong Kong stock sectors, with only 9 pharmaceutical companies listed in the U.S stock sector In recent years, the number of new listed companies in Hong Kong stock market has increased year by year, reaching a record high of 19 in 2019 By the end of 2019, there are 70 companies listed on the science and technology innovation board, of which 17 are biomedical companies, accounting for more than one fifth The preference of pharmaceutical enterprises for scientific and technological innovation board also reflects the inevitable trend of transformation and upgrading of the industry to R & D innovation Figure 3 number of pharmaceutical and biological companies listed in various sectors in 2010-2019